Edition:
United Kingdom

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

113.45GBp
20 Mar 2019
Change (% chg)

2.45 (+2.21%)
Prev Close
111.00
Open
111.40
Day's High
114.25
Day's Low
108.55
Volume
1,841,732
Avg. Vol
3,511,438
52-wk High
504.60
52-wk Low
75.48

Chart for

About

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue... (more)

Overall

Beta: --
Market Cap(Mil.): £2,498.61
Shares Outstanding(Mil.): 721.46
Dividend: --
Yield (%): --

Financials

  INDV.L Industry Sector
P/E (TTM): 48.23 29.30 32.54
EPS (TTM): 0.07 -- --
ROI: 25.75 14.23 13.82
ROE: -- 15.46 15.25

Indivior launches generic version of its Suboxone opioid drug

British drugmaker Indivior Plc said on Wednesday it had launched a copycat version of its blockbuster opioid addiction drug Suboxone in the United States, just one day after a court decision cleared the way for its rivals to market generic versions of it.

20 Feb 2019

UPDATE 2-Indivior launches generic version of its Suboxone opioid drug

* Indivior says launches generic version of Suboxone in U.S. market

20 Feb 2019

REFILE-Indivior launches generic version of opioid drug after losing court battle

Feb 20 Indivior Plc has launched a copycat of its blockbuster opioid addiction drug in the United States, the British drugmaker said on Wednesday, after losing a long-drawn court battle to prevent entry of generic rivals in its biggest market.

20 Feb 2019

U.S. top court rejects bid to block Indivior opioid drug copycat

WASHINGTON The U.S. Supreme Court dealt a blow to Indivior Plc on Tuesday, clearing the way for a copycat version of the British pharmaceutical firm's lucrative opioid addiction treatment Suboxone Film in a victory for India-based generic drug maker Dr. Reddy's Laboratories.

19 Feb 2019

U.S. top court rejects bid to block Indivior opioid drug copycat

WASHINGTON, Feb 19 The U.S. Supreme Court dealt a blow to Indivior Plc on Tuesday, clearing the way for a copycat version of the British pharmaceutical firm's lucrative opioid addiction treatment Suboxone Film in a victory for India-based generic drug maker Dr. Reddy's Laboratories .

19 Feb 2019

Indivior 2018 operating profit rises 51 pct on lower expenses

Feb 14 Drugmaker Indivior Plc reported a rise in full-year operating profit on Thursday, helped by lower operating expenses as it braces for the launch of cheaper copies of its blockbuster drug Suboxone after a long patent battle in U.S. courts.

14 Feb 2019

Indivior loses U.S. district court battle, copycat launches imminent

Generic competitors to British drugmaker Indivior Plc's blockbuster opioid addiction treatment are on course to launch sales next week after the firm's attempt to stay a U.S. District court judgement was rejected.

12 Feb 2019

Indivior loses U.S. district court battle, copycat launches imminent

Generic competitors to British drugmaker Indivior Plc's blockbuster opioid addiction treatment are on course to launch sales next week after the firm's attempt to stay a U.S. District court judgement was rejected.

12 Feb 2019

Indivior loses U.S. district court battle, copycat launches imminent

Feb 12 Generic competitors to British drugmaker Indivior Plc's blockbuster opioid addiction treatment are on course to launch sales next week after the firm's attempt to stay a U.S. District court judgement was rejected.

12 Feb 2019

UPDATE 2-UK Stocks-Factors to watch on Feb. 4

Feb 4 Britain's FTSE 100 index is seen opening 1 point higher at 7,021 on Monday, according to financial bookmakers, with FTSE 100 futures down 0.08 percent ahead of the cash market open.

04 Feb 2019

Earnings vs. Estimates